Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :458
Small font sizeDefault font sizeIncrease font size
Navigate here
  Search
 
  
Resource links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (945 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
  Acknowledgment
   References
   Article Figures

 Article Access Statistics
    Viewed623    
    Printed11    
    Emailed0    
    PDF Downloaded96    
    Comments [Add]    

Recommend this journal

 


 
  Table of Contents  
LETTER TO THE EDITOR
Year : 2015  |  Volume : 52  |  Issue : 3  |  Page : 395-396
 

Prolonged survival of a patient with inoperable, locally advanced adenocarcinoma of pancreas after autologous immune enhancement therapy with chemotherapy


1 The Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India
2 The Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India
3 Division of Immunology, Biotherapy Institute of , Tokyo, Japan
4 Department of Surgery, Srushti Hospital, Chennai, India
5 Department of Regenerative Medicine, Deepam Hospitals, Chennai, India
6 The Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India; Department of Clinical Research, Yamanashi University-School of Medicine, Chuo, Japan

Date of Web Publication18-Feb-2016

Correspondence Address:
SJK Abraham
The Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai; Department of Clinical Research, Yamanashi University-School of Medicine, Chuo

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-509X.176721

Rights and Permissions



How to cite this article:
Baskar S, Dedeepiya V D, Terunuma H, Manjunath S R, Senthilkumar R, Sivaraman G, Pandian A, Abraham S. Prolonged survival of a patient with inoperable, locally advanced adenocarcinoma of pancreas after autologous immune enhancement therapy with chemotherapy. Indian J Cancer 2015;52:395-6

How to cite this URL:
Baskar S, Dedeepiya V D, Terunuma H, Manjunath S R, Senthilkumar R, Sivaraman G, Pandian A, Abraham S. Prolonged survival of a patient with inoperable, locally advanced adenocarcinoma of pancreas after autologous immune enhancement therapy with chemotherapy. Indian J Cancer [serial online] 2015 [cited 2017 Jul 20];52:395-6. Available from: http://www.indianjcancer.com/text.asp?2015/52/3/395/176721


Sir,

Life expectancy in advanced pancreatic cancers is only about nine to ten months with the current treatments including Chemotherapy.[1] Herein we report a 26 month survival of a pancreatic cancer patient treated with Autologous Immune Enhancement Therapy (AIET) and chemotherapy.

A 40 year old male patient with no family history of cancer presented with symptoms of Obstructive jaundice, loss of weight and appetite, pale stools and new onset Diabetes Mellitus in January 2007. Examination showed a palpable gallbladder without lymphadenopathy. The Haemoglobin level was 10.5 g/dl; Tumour marker CA-125 was 4.0 U/ml and CA 19-9 was 3900 U/ml. Further investigations revealed Carcinoma of the pancreatic head involving uncinate process with the tumour measuring 4.2 × 3.2 cm and the Common Bile Duct (CBD) measuring 1.9 cm without involvement of the Superior mesenteric vein. Endoscopic retrograde cholangiopancreatography showed it to be a moderately differentiated Grade III Adenocarcinoma. CBD stenting was done in February 2007. Palliative surgery of Cholecystectomy, hepatico-jejunostomy using Roux-n-Y loop of jejunum, Gastrojejunostomy and jejuno-jejunostomy were done. Subsequently, he was administered six cycles of adjuvant chemotherapy (Gemcitabine, Leucovorin and 5-FU) and three cycles of AIET, as AIET has a proven record of safety for more than two decades with randomised clinical trials establishing its efficacy.[2] After informed consent, 60 mL of Peripheral Blood (PB) was collected for each cycle of AIET. The Natural Killer (NK) Cells and Cytotoxic T lymphocytes were isolated and expanded following GMP compliant protocols using the patients' autologous plasma as earlier reported [3],[4] without using any feeder layers or animal products or allogeneic serum. The cells multiplied were subjected to flow cytometry for CD3, CD56, CD16, CD34, CD45 and HLADR markers which showed an increased activation of expanded lymphocytes [Figure 1]a, [Figure 1]b. Activated and expanded cells were infused intravenously.
Figure 1: (a) Flow cytometry image of CD3 + lymphocytes from the peripheral blood before expansion and activation; (b) The same after in vitro expansion and activation; (c) The gradual decrease of CA 19-9 levels during the course of treatment

Click here to view


The first AIET infusion was given between the second and third chemotherapy cycles in April 2007 and the second infusion after the completion of six cycles of chemotherapy in December 2007. The tumour marker CA 19-9 decreased to 1000 U/ml. Surgical removal of the tumour was attempted after the second AIET but in vain. In March 2008, the third AIET was administered. The average count of lymphocytes infused was 61.3 millions. The CA 19-9 decreased further to 600 U/ml after the third AIET [Figure 1]c. The patient had subjective improvements in appetite and quality of life. He survived for 26 months after the initial diagnosis while the expected survival in these patients as per reported literatures is less than 10 months.[1] This is in line or even longer than that reported by Kaneko et al. in which the survival time of immunotherapy combined with chemotherapy was 15.8 months in 28 patients with advanced pancreatic cancers.[5] The patient did not have any kind of adverse reactions after the AIET transfusions. With our experience in this case, where AIET given in combination with chemotherapy has resulted in prolonged survival of 26 months in an inoperable advanced pancreatic carcinoma patient, we recommend that this option be considered for similar cases.


  Acknowledgment Top


M/S Hope Foundation (Trust), Chennai, India for funding the study. Dr. Preethy Senthilkumar for her assistance in drafting the manuscript.

 
  References Top

1.
Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.  Back to cited text no. 1
    
2.
Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 2000;356:802-7.  Back to cited text no. 2
    
3.
Takada M, Terunuma H, Deng X, Dewan MZ, Saji S, Kuroi K, et al. Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach, Breast Cancer 2011;18:64-7.  Back to cited text no. 3
    
4.
Dedeepiya V, Terunuma H, Deng X, Baskar S, Manjunath S, Senthilkumar R, et al. A comparative analysis of in vitro expansion of natural killer cells of a patient with autoimmune haemolytic anaemia and ovarian cancer with patients with other solid tumours. Oncology Lett 2011;3:435-40.  Back to cited text no. 4
    
5.
Kaneko T, Goto S, Kato A, Akeyama A, Tomonaga M, Fujimoto K, et al. Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer. Anticancer Res 2005;25:3709-14.  Back to cited text no. 5
    


    Figures

  [Figure 1]



 

Top
Print this article  Email this article
 

    

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow